用于药物开发应用的全人肝培养系统

Executive Industry Relevance

Long-term, human-relevant hepatic models are critical for predictive drug metabolism and toxicity assessment in early drug development. The TV2D+ all-human hepatic culture system enables robust, reproducible evaluation of primary human hepatocytes using standard 2D workflows, supporting portfolio-wide risk reduction. This platform addresses the need for scalable, phenotypically stable models that enhance translational confidence and streamline preclinical decision-making.

Strategic Applications in Biopharma R&D

Early Discovery & Target Validation

• Enables interrogation of hepatic drug metabolism pathways using primary human cells.
• Supports functional validation of hepatic targets through sustained marker expression and viability.
• Facilitates mechanistic de-risking by maintaining physiologically relevant albumin and urea levels.

Screening & Assay Development

• Provides a reproducible, scalable platform for compound screening in a human hepatic context.
• Ensures assay standardization and quantitative output across multiple PHH lots and seeding densities.
• Supports reliable evaluation of metabolic clearance and pharmacokinetic properties.

Translational & Preclinical Research

• Aligns in vitro hepatic function with preclinical biomarker requirements for translational continuity.
• Enables risk-adjusted advancement decisions by predicting human-relevant drug metabolism and toxicity.
• Maintains architectural integrity and viability for extended preclinical studies.

Pipeline & Workflow Integration

The TV2D+ system integrates into the discovery-to-preclinical continuum, bridging early target validation, compound screening, and translational research.

• Discovery Biology: Supports hypothesis testing and pathway clarification in human hepatocytes.
• Screening: Delivers reproducible, quantitative metabolic and viability readouts for compound triage.
• Analytics: Enables measurement of albumin, urea, and metabolic clearance for comparative analysis.
• Translational Research: Provides continuity from in vitro findings to preclinical biomarker alignment.
• Enterprise Reuse: Offers a standardized, flexible platform adaptable across drug development programs.

Operational & Enterprise Impact

• Scientific Value: Increases predictive confidence in human drug metabolism and toxicity outcomes.
• Operational Value: Simplifies workflows with standard equipment and robust reproducibility.
• Strategic Value: Improves go/no-go decisions and reduces late-stage attrition risk.
• Portfolio Impact: Enables risk-adjusted prioritization and efficient resource allocation.

Implementation Considerations

• Requires expertise in primary human hepatocyte culture and standard aseptic technique.
• Utilizes conventional 2D culture equipment and analytical infrastructure.
• Demands cross-team standardization for reproducible results across PHH lots.
• Adaptable to various seeding densities and experimental designs.
• Dependent on quality and availability of primary human hepatocytes.

Biopharma FAQs